CLEVELAND--(BUSINESS WIRE)--Cleveland Diagnostics, Inc., a clinical-stage company focused on developing next-generation diagnostic tests for the detection of cancers, today announced that its chief medical officer, Mark Stovsky, MD, participated in an Impact Session at the 2019 Medical Innovation Summit organized by Cleveland Clinic.
The Medical Innovation Summit, which is celebrating its 17th year, is covering a wide range of topics including artificial intelligence, new drug discovery, advanced diagnostics development, and the personalization of healthcare. Clinicians, strategists, venture capital groups and other ground-breakers joined renowned clinical experts to discuss, disrupt and deal head-on with issues confronting today's healthcare ecosystem.
During the Impact Session entitled “Early Detection: A Snag in the System,” Dr. Stovsky, CMO of Cleveland Diagnostics and urologist at the Cleveland Clinic, joined other leading industry and government experts to discuss current challenges and opportunities in early detection in cancer. Other topics included early diagnosis of untreatable diseases and the subsequent lack of protocol to move forward.
“We are indeed honored to have Dr. Stovsky join a distinguished panel of speakers on cancer early detection at this meeting,” said Arnon Chait, PhD, CEO of Cleveland Diagnostics. “The discussion was both timely and enlightening, and it is clear that some of the leading players in the space are finally beginning to refocus resources on early cancer detection as perhaps the only viable long-term and cost-effective solution to curable approaches in cancer.”
Cleveland Diagnostics was recently awarded Breakthrough Device Designation by FDA, which allows Cleveland Diagnostics to work more closely and frequently with FDA to expedite the review of its prostate cancer assay, IsoPSA®. Two recent multicenter clinical trials, in which the diagnostic accuracy of IsoPSA was compared to that of traditional prostate-specific antigen (PSA), suggested that IsoPSA has superior diagnostic accuracy in detecting high-grade prostate cancer. Cleveland Diagnostics has a pipeline of simple, cancer-specific and highly cost effective cancer blood tests using the same proprietary core technology.
“The traditional approach to early detection strategies for prostate cancer based on standard serum PSA testing is limited by relatively poor diagnostic accuracy and predictive value. We believe the IsoPSA assay will fill a major gap in this space by providing clinicians with a tool that has improved diagnostic accuracy - particularly for the detection of high grade, clinically actionable prostate cancer," said Dr. Stovsky. "I am thrilled to have had the opportunity to join industry and government leaders, such as Grail, Intel, and NCI, to discuss innovative ways to develop more effective approaches to cancer early detection that will improve the lives of patients worldwide. While we believe that the IsoPSA assay will improve early detection strategies for prostate cancer, we also look forward to exploring ways to work together to design a clinically superior, cost effective early detection paradigm, which might combine virtual screening, protein biomarker testing -- such as IsoPSA -- and DNA liquid biopsy as a comprehensive approach to this challenging clinical problem.”
About Cleveland Diagnostics, Inc.
Cleveland Diagnostics, Inc., is a clinical-stage biotechnology company developing technology to improve cancer diagnostics. Its Solvent Interaction Analysis™ (SIA) technology investigates biomarkers at the structural level as opposed to overall concentration, giving better insights as to the protein origin. Its portfolio of non-invasive cancer diagnostics include prostate cancer, breast cancer, and Alzheimer’s disease. Visit us at cleveland-diagnostics.com.